Gilead Sciences Inc.’s stock rose 2% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.
The number of Americans who applied for unemployment benefits in the week before the Thanksgiving holiday dipped to a seven-month low in a sign of strength for a steadily expanding U.S. economy.